September 10, 2012
Eisai announced on September 7 that its Australian marketing subsidiary Eisai Australia Pty. Ltd. received approval on August 31 from the Australian Department of Health and Aging to market the breast cancer treatment Halaven (eribulin mesylate). The company will begin...read more